Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Bliuc, D
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. [electronic resource] - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA Apr 2019 - 817-828 p. digital
Publication Type: Journal Article; Multicenter Study; Observational Study
1433-2965
10.1007/s00198-018-4806-0 doi
Aged
Alendronate--therapeutic use
Bone Density Conservation Agents--therapeutic use
Canada--epidemiology
Diphosphonates--therapeutic use
Etidronic Acid--therapeutic use
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Osteoporosis--drug therapy
Osteoporotic Fractures--mortality
Prospective Studies
Risedronic Acid--therapeutic use
Risk Factors
Risk Reduction Behavior
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. [electronic resource] - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA Apr 2019 - 817-828 p. digital
Publication Type: Journal Article; Multicenter Study; Observational Study
1433-2965
10.1007/s00198-018-4806-0 doi
Aged
Alendronate--therapeutic use
Bone Density Conservation Agents--therapeutic use
Canada--epidemiology
Diphosphonates--therapeutic use
Etidronic Acid--therapeutic use
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Osteoporosis--drug therapy
Osteoporotic Fractures--mortality
Prospective Studies
Risedronic Acid--therapeutic use
Risk Factors
Risk Reduction Behavior